Introduction

According to the Global Burden of Disease Study 2010, stroke was the third leading cause of disability-adjusted life years (DALYs) worldwide [1]. The same study showed that in China, cardiovascular diseases (stroke and ischemic heart disease) were the leading cause of DALYs, and stroke was the leading cause of death [2]. Atherosclerosis is the most common cause of stroke. The development of atherosclerosis was not only associated with dyslipidemia [3], but also closely associated with inflammation. The later was linked to the complexity and instability of plaques [4]. C-reactive protein (CRP), an indicator of systemic inflammation, may predict the burden of atherosclerosis [5,6].

Although many studies showed that CRP was associated with increased risk of stroke [7–10], others did not find the significant association [11,12]. Most of these studies with positive findings focused on ischemic stroke. In addition, most of these studies were in Europe and America with majority of non-Asian population. It has been shown that Asians tend to have higher concentrations of CRP than European whites [13]. To our knowledge there is no large scale study on CRP as a risk factor of stroke or its subtypes in Chinese. We therefore conducted a large prospective study to investigate the relationship between CRP concentrations and stroke and its subtypes, i.e. ischemic stroke (IS), hemorrhagic stroke (ICH) and subarachnoid hemorrhage (SAH) using samples from Kailuan Study.
Methods

Study Design and Population

The Kailuan study was a longitudinal, ongoing community health study based on Kailuan community in Tangshan city, which is a large and littoral modern city located in the southeast of Beijing. From June 2006 to October 2007, all employees (including the retired) in the community (155,418) were invited to participate the study, and 65.3% of them agreed. After screening against the inclusion criteria (1) aged 18 years or older; (2) providing written informed consent; and (3) updating their health status every year and biennial measurements of the below parameters according to the follow-up protocol, 101,510 participants (81,110 men and 20,400 women, aged 18–98 years old) were recruited into the Kailuan study. All participants underwent a questionnaire survey, clinical examination, and laboratory testing, which were conducted in the 11 hospitals in Kailuan community, following standard protocols described previously [14].

In this study, we excluded subjects who had a history of myocardial infarction (MI) [1,112], stroke [2,355], or both [205] at baseline. Because hs-CRP concentrations >10.0 mg/L suggesting an acute inflammation, we also excluded participants with hs-CRP concentrations >10.0 mg/L [7,323], leaving 90,517 subjects included in the analyses. This study was performed according to the guidelines of Helsinki Declaration and was approved by the Ethics Committees of Kailuan General Hospital, Beijing Chaoyang Hospital and Beijing Tiantan Hospital, as a collaborative project.

Assessment of Stroke and stroke subtypes

The primary outcome was the first incidence of stroke, either nonfatal or fatal. The diagnosis of stroke was made according to World Health Organization (WHO) criteria [15] confirmed with brain computed tomography (CT) or magnetic resonance (MR), and classified into one of the three subtypes: IS, ICH, or SAH, following unified protocol. A nonfatal stroke was defined as a focal neurological deficit of sudden onset and vascular mechanism that lasted >24 hours. Fatal stroke were the deaths caused by a confirmed cerebrovascular mechanism.

The stroke history of all participants was recorded biennially at clinic visits or telephone interviews from the baseline survey through December 31, 2010, or to the date of death or loss to follow-up. The results were confirmed by hospital discharge summaries or death certificates.

Assessment of Variables

Information on demographic variables (e.g. age, sex), smoking and alcohol habit, and past medical history were collected via questionnaires administered by the research doctors at the baseline interview. Hypertension was defined by the presence of any of the following: a history of hypertension, using antihypertensive treatment, a systolic blood pressure ≥140 mmHg, or a diastolic pressure ≥90 mmHg. Diabetes mellitus was diagnosed by the presence of any of the following: a history of diabetes mellitus, currently treated with insulin or oral hypoglycemic agents, or the fasting blood glucose level was ≥7.0 mmol/L. Hyperlipidemia was defined by the presence of any of the following: a history of hyperlipidemia, current use of cholesterol lowering agents, or the total cholesterol level ≥5.17 mmol/L or triglyceride ≥1.7 mmol/L.

Body weight, height and blood pressure (Bp) were measured during the baseline interview, and body mass index (BMI) was calculated. Bp was the average of at least two readings at rest.

Blood samples were obtained after an overnight fast in EDTA tubes at the baseline interview. Fasting blood glucose was measured with the hexokinase/glucose-6-phosphate dehydrogenase method. Cholesterol and triglyceride were measured enzymatically (Mind Bioengineering Co. Ltd, Shanghai, China). High-sensitivity (Hs)-CRP was measured by high-sensitivity nephelometry assay (Cias Latex CRP-H, Kanto Chemical Co. Inc, Tokyo, Japan). All blood variables were measured using an auto-analyzer (Hitachi 747; Hitachi, Tokyo, Japan) at the central laboratory of the Kailuan General Hospital. According to the guideline from the centers for Disease Control and Prevention and the American Heart Association, hs-CRP concentrations were categorized into three groups: hs-CRP<1 mg/L, hs-CRP 1 to 3 mg/L, and hs-CRP>3 mg/L [16].

Statistical Analysis

Statistical analyses were performed using SAS software, version 9.1 (SAS Institute, Cary, North Carolina, USA). As all the continuous variables were in skewed distribution, median were used for analysis, and compared using analysis of variance (ANOVA). Hs-CRP was log-transformed as a continuous variable to fit a less skewed distribution. Categorical variables were described by percentages, and compared using Chi-Square tests. Direct standardization method was used to calculate the age- and sex-standardized incidence rates according the National population census in 2010. Hazard ratios (HRs) and 95% confidence intervals (CI) of stroke and its subtypes were estimated according to different hs-CRP concentrations and 1-SD increment of log-transformed hs-CRP (antilog of SD = 3.0 mg/L) with Cox proportional hazards regression models [17]. Adjustment was made for age, sex, hypertension, diabetes, dyslipidemia and for SBP, DBP, BMI, TC, TG, LDL, GLU, current smoking, alcohol intake, and antihypertensive treatment, lipid-lowering treatment, hypoglycemic treatment were also conducted. The Kaplan-Meier curves for cumulative stroke and its subtypes were plotted according to hs-CRP concentrations and compared with the log-rank test. Receiver Operating Characteristic (ROC) analysis was used to determine the cut-off-points of hs-CRP concentrations for the prediction of all stroke and stroke subtypes, as well as their predicted efficiency. All statistical tests were 2-sided, and the significant level was set at 0.05.

Results

Baseline characteristics according to hs-CRP concentrations were presented in Table 1. Male subjects were in higher proportion (79.5%) in the study. Subjects in the groups of higher hs-CRP concentrations (≥1 mg/L) were older. High hs-CRP concentrations (≥1 mg/L) were associated with higher prevalence of traditional stroke risk factors, including hypertension (both systolic and diastolic), diabetes, dyslipidemia, high BMI, and elevated concentrations of fasting glucose, total cholesterol (TC), triglycerides (TG) and low-density lipoprotein cholesterol (LDL). Interestingly, of the three groups, the concentrations of TG, TC, LDL and the prevalence of dyslipidemia, current smoking/alcohol intake, and taking antihypertensive/hypoglycemic drug therapy were the highest in the hs-CRP of 1 to 3 mg/L group.

The total follow-up time was 362,165 person-years, with a median follow-up time of 49 months per participants. At the end of the study, we identified 1,472 new stroke cases, of which 1,049 (71.3%) were IS, 383 (26%) were ICH, and 40 (2.7%) were SAH. The age- and sex-standardized incidence per 1000 person-years of all stroke and stroke subtypes in this cohort according to
hs-CRP concentrations were shown in Table 2. The incidence rates of IS and ICH increased with hs-CRP concentrations.

Table 3 showed the hazard ratios (HR) of all stroke and its subtypes according to serum hs-CRP concentrations using Cox proportional hazards models. In unadjusted models, elevated hs-CRP concentrations were associated with significant high risk of all stroke, IS and ICH, respectively. Adjusting for age and sex did not attenuate the trend in all stroke and IS in both groups of elevated hs-CRP groups ($1 \text{ mg/L}$). After multivariate adjustment, elevated hs-CRP concentrations ($1 \text{ mg/L}$) showed persistent association with increased risk of all stroke and IS. However, elevated hs-CRP ($1 \text{ mg/L}$) was not significantly associated with the risk of ICH after adjusting for age and sex and multivariate adjustment (Table 3). There was no significant association between hs-CRP concentrations and the risk of SAH.

To further explore the effects of hs-CRP on the outcome of stroke, and sex difference, subgroup analyses were conducted in fatal/non-fatal stroke, male/female and participants with/without hypertension (Table 4). It showed that elevated hs-CRP was a risk factor for non-fatal all stroke, and non-fatal IS. Elevated hs-CRP had significant effect on male subjects in all stroke and IS. Elevated hs-CRP was not associated with fatal stroke, and had no significant effect on female.

Because hypertension is an independent risk factor for hemorrhagic stroke, to further explore the potential association between hs-CRP and hemorrhagic stroke, subgroup analysis was carried out based on hypertension status (yes/no) (Table 4). Hs-

<table>
<thead>
<tr>
<th>hs-CRP</th>
<th>All stroke</th>
<th>IS</th>
<th>ICH</th>
<th>SAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1 mg/L</td>
<td>9.89</td>
<td>6.51</td>
<td>3.04</td>
<td>0.33</td>
</tr>
<tr>
<td>1–3 mg/L</td>
<td>13.95</td>
<td>9.52</td>
<td>4.36</td>
<td>0.68</td>
</tr>
<tr>
<td>&gt;3 mg/L</td>
<td>18.49</td>
<td>13.24</td>
<td>4.61</td>
<td>0.64</td>
</tr>
</tbody>
</table>

Table 2. The age- and sex-standardized incidence per 1000 person-years of stroke subtypes according to hs-CRP concentrations.
Table 3. Hazard ratios (HR) and 95% confidence intervals (95% CI) of all stroke and stroke subtypes according to serum hs-CRP concentrations.

<table>
<thead>
<tr>
<th>hs-CRP</th>
<th>&lt;1 mg/L</th>
<th>1–3 mg/L</th>
<th>&gt;3 mg/L</th>
<th>1SD increment of log hs-CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>All stroke N(%)</td>
<td>652(1.24)</td>
<td>440(1.87)</td>
<td>380(2.61)</td>
<td></td>
</tr>
<tr>
<td>Crude Model 1.00(Reference)</td>
<td>1.50(1.33–1.69)**</td>
<td>1.80(1.56–2.09)**</td>
<td>1.32(1.24–1.40)**</td>
<td></td>
</tr>
<tr>
<td>Model 1 1.00(Reference)</td>
<td>1.32(1.17–1.49)**</td>
<td>1.45(1.24–1.68)**</td>
<td>1.18(1.11–1.26)**</td>
<td></td>
</tr>
<tr>
<td>Model 2 1.00(Reference)</td>
<td>1.71(1.03–1.33)*</td>
<td>1.25(1.07–1.46)*</td>
<td>1.09(1.02–1.16)*</td>
<td></td>
</tr>
<tr>
<td>IS N(%)</td>
<td>442(0.84)</td>
<td>315(1.34)</td>
<td>292(2.00)</td>
<td></td>
</tr>
<tr>
<td>Crude Model 1.00(Reference)</td>
<td>1.55(1.34–1.80)**</td>
<td>1.99(1.67–2.37)**</td>
<td>1.42(1.32–1.53)**</td>
<td></td>
</tr>
<tr>
<td>Model 1 1.00(Reference)</td>
<td>1.35(1.17–1.56)**</td>
<td>1.58(1.32–1.88)**</td>
<td>1.26(1.17–1.36)**</td>
<td></td>
</tr>
<tr>
<td>Model 2 1.00(Reference)</td>
<td>1.17(1.01–1.36)*</td>
<td>1.33(1.11–1.60)*</td>
<td>1.15(1.06–1.24)**</td>
<td></td>
</tr>
<tr>
<td>ICH N(%)</td>
<td>192(0.37)</td>
<td>111(0.47)</td>
<td>80(0.55)</td>
<td></td>
</tr>
<tr>
<td>Crude Model 1.00(Reference)</td>
<td>1.35(1.07–1.71)*</td>
<td>1.43(1.05–1.93)*</td>
<td>1.11(0.99–1.24)</td>
<td></td>
</tr>
<tr>
<td>Model 1 1.00(Reference)</td>
<td>1.22(0.96–1.55)</td>
<td>1.18(0.86–1.61)</td>
<td>1.02(0.91–1.14)</td>
<td></td>
</tr>
<tr>
<td>Model 2 1.00(Reference)</td>
<td>1.15(0.90–1.47)</td>
<td>1.09(0.79–1.50)</td>
<td>0.97(0.86–1.08)</td>
<td></td>
</tr>
<tr>
<td>SAH N(%)</td>
<td>18(0.03)</td>
<td>14(0.06)</td>
<td>8(0.05)</td>
<td></td>
</tr>
<tr>
<td>Crude Model 1.00(Reference)</td>
<td>1.57(0.78–3.19)</td>
<td>0.96(0.33–2.79)</td>
<td>1.32(0.90–1.93)</td>
<td></td>
</tr>
<tr>
<td>Model 1 1.00(Reference)</td>
<td>1.49(0.73–3.04)</td>
<td>0.87(0.30–2.59)</td>
<td>1.27(0.86–1.87)</td>
<td></td>
</tr>
<tr>
<td>Model 2 1.00(Reference)</td>
<td>1.29(0.63–2.65)</td>
<td>0.69(0.22–2.15)</td>
<td>1.14(0.76–1.70)</td>
<td></td>
</tr>
</tbody>
</table>

*P<0.05, **P<0.001.

hs-CRP: high-sensitivity C-reactive protein; ICH: intracranial hemorrhage; IS: ischemic stroke; SAH: subarachnoid hemorrhage.

Model 1: adjusted for age and sex.

Model 2: adjusted for Model 1 and for hypertension, diabetes, dyslipidemia and for SBP, DBP, BMI, TC, TG, LDL, GLU, current smoking, alcohol intake, antihypertensive treatment, lipid-lowering treatment and hypoglycemic treatment.

doi:10.1371/journal.pone.0107017.t003

CRP≥1 mg/L was a risk factor for all stroke and IS in patients with hypertension, but in participants without hypertension, only hs-CRP>3 mg/L was a risk factor for all stroke and IS. Elevated hs-CRP concentrations again were not associated with the risk of ICH and SAH, regardless of hypertension status.

The Kaplan-Meier plot of stroke and stroke subtypes according to the concentrations of hs-CRP showed the cumulative incidence rates of all stroke, IS and ICH were associated with elevated hs-CRP concentrations, but not with SAH (Figure 1). Further ROC analysis showed the cut-off-points of hs-CRP concentrations for all stroke, IS and ICH were 1.34 mg/L, 1.01 mg/L and 0.84 mg/L, respectively, and the areas under ROC curve were 0.592, 0.611 and 0.537, correspondingly.

**Discussion**

Previous studies showed that CRP concentrations were modestly associated with the risk of IS [8,10,18] and transient ischemic attack (TIA) [10] in middle-aged [18] and elderly individuals [8,10]. Most of these were American studies, and focused on IS. In a Japanese retrospective study, elevated CRP concentrations were associated with higher incidence of all stroke and IS, but not hemorrhagic stroke [17]. There was also a study showed high CRP level was a strong risk factor for fatal stroke [19]. Based on these studies, we conducted this community based, prospective study to explore the relationship between CRP concentrations and the incidence of stroke and its subtypes in Chinese. In this large study of 90,517 Chinese, we confirmed that elevated hs-CRP concentrations were significantly associated with increased risk of all stroke and IS, but not ICH and SAH. The higher hs-CRP concentrations, the higher incidence rates of all stroke, IS and ICH, but not that of SAH.

The pathophysiological mechanism of the association between elevated CRP concentrations and the risk of stroke is yet fully elucidated. CRP is an indicator of inflammation, both acute and chronic systemic inflammation [20]. Inflammation may promote thrombosis and vascular injury, which are responsible for most cardiovascular diseases [21]. Studies suggested that inflammation may affect the composition, morphology and stability of atherosclerotic plaque [4,5]. An autopsy study demonstrated the existence of CRP in the atherosclerotic coronary arteries but not in the normal ones; and the intensity of CRP staining was correlated with the relative intimal thickness [22]. CRP may also promote thrombotic events by inducing monocytes to express tissue factor, a potent procoagulant [23]. Because large-artery atherosclerosis is the most common cause of IS [24], our clinical findings are in line with those studies [7–10,17–19], showing that the elevated CRP concentrations are associated with increased risk of IS.

Research on the relationship between CRP and ICH was scarce, with limited data suggesting that CRP concentrations are not associated with ICH [17,25,26]. However, this study demonstrated, at least a trend, that with the increase of hs-CRP concentrations, the incidence of ICH increased. There were studies showed that CRP concentrations were associated with white matter lesions, suggesting inflammatory process involvement in the pathogenesis of cerebral small vessel disease [27]. It is known that ICH can be due to the rupture of small vessels from lipohyalinosis secondary to hypertension [28], or by amyloid angiopathy [29]. The relationship between CRP and ICH was...
further demonstrated by a study showing hs-CRP concentrations were associated with cerebral microbleeds, in both lobar and deep locations [30]. Cerebral microbleeds were strongly associated with the occurrence of ICH [31]. Thus, the finding in our study was not completely unexpected, although the results from multivariant adjustment suggesting elevated hs-CRP may not be an independent risk factor for ICH, or it may be only associated with certain subtype of ICH that associated with inflammation. This is in agreement with previous studies.

The results of the relationship between hs-CRP and SAH were similar to previous studies [26,32] in which hs-CRP concentrations were not associated with the SAH risk. This might be due to the main risk factors for SAH are current smoking, hypertension and alcohol intake [33], and atherosclerosis plays a weak role in intracranial aneurysm [34]. It might also be possible that the incidence of SAH is very low, nearly 10.5 per 100,000 person years [35], which made this study under-powered to detect the significance.

The current study is a large-scale community based study, with a good number of incident stroke cases. There are also some methodological strengths, such as prospective design, and detailed follow-up and data collection. However, this study had some limitations. First, during the follow-up, some participants might start or withdraw lipid-lowering treatment, which might affect Table 4. Subgroup Analysis of hazard ratios (HR) and 95% confidence intervals (95% CI) of all stroke and stroke subtypes according to serum hs-CRP concentrations.

<table>
<thead>
<tr>
<th>hs-CRP</th>
<th>&lt;1 mg/L</th>
<th>1–3 mg/L</th>
<th>&gt;3 mg/L</th>
<th>HR for 1SD increment of log hs-CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatal stroke</td>
<td>All/IS/ICH/SAH, n</td>
<td>59/30/24/5</td>
<td>36/23/12/1</td>
<td>36/27/8/1</td>
</tr>
<tr>
<td>All stroke Model 2</td>
<td>1.00 (Reference)</td>
<td>1.08 (0.71–1.66)</td>
<td>1.17 (0.69–1.97)</td>
<td>1.13 (0.91–1.39)</td>
</tr>
<tr>
<td>IS Model 2</td>
<td>1.00 (Reference)</td>
<td>1.32 (0.75–2.30)</td>
<td>1.68 (0.89–3.17)</td>
<td>1.38 (0.99–1.80)</td>
</tr>
<tr>
<td>ICH Model 2</td>
<td>1.00 (Reference)</td>
<td>0.97 (0.48–1.99)</td>
<td>0.72 (0.25–2.02)</td>
<td>0.92 (0.66–1.28)</td>
</tr>
<tr>
<td>SAH Model 2</td>
<td>1.00 (Reference)</td>
<td>0.24 (0.03–2.27)</td>
<td>0.12 (0.00–3.50)</td>
<td>0.63 (0.27–1.48)</td>
</tr>
<tr>
<td>Non-fatal stroke</td>
<td>All/IS/ICH/SAH, n</td>
<td>593/412/168/13</td>
<td>404/292/99/13</td>
<td>344/265/72/7</td>
</tr>
<tr>
<td>All stroke Model 2</td>
<td>1.00 (Reference)</td>
<td>1.18 (1.04–1.35)*</td>
<td>1.26 (1.07–1.48)*</td>
<td>1.09 (1.02–1.16)*</td>
</tr>
<tr>
<td>IS Model 2</td>
<td>1.00 (Reference)</td>
<td>1.16 (1.00–1.36)</td>
<td>1.31 (1.08–1.58)*</td>
<td>1.13 (1.04–2.23)*</td>
</tr>
<tr>
<td>ICH Model 2</td>
<td>1.00 (Reference)</td>
<td>1.18 (0.91–1.53)</td>
<td>1.15 (0.82–1.61)</td>
<td>0.98 (0.87–1.10)</td>
</tr>
<tr>
<td>SAH Model 2</td>
<td>1.00 (Reference)</td>
<td>1.77 (0.80–3.90)</td>
<td>0.97 (0.29–3.25)</td>
<td>1.31 (0.84–2.06)</td>
</tr>
</tbody>
</table>

| Male | All/IS/ICH/SAH, n | 588/402/171/15 | 387/281/96/10 | 326/257/64/5 |
| All stroke Model 2 | 1.00 (Reference) | 1.15 (1.01–1.31)* | 1.25 (1.06–1.48)* | 1.09 (1.02–1.17)* |
| IS Model 2 | 1.00 (Reference) | 1.16 (0.99–1.36) | 1.37 (1.13–1.66)* | 1.07 (1.04–1.11)* |
| ICH Model 2 | 1.00 (Reference) | 1.13 (0.87–1.46) | 1.00 (0.70–1.43) | 1.01 (0.96–1.17) |
| SAH Model 2 | 1.00 (Reference) | 1.10 (0.48–2.49) | 0.58 (0.15–2.23) | 0.97 (0.76–1.18) |

| Female | All/IS/ICH/SAH, n | 64/40/21/3 | 53/34/15/4 | 54/35/16/3 |
| All stroke Model 2 | 1.00 (Reference) | 1.36 (0.93–2.00) | 1.29 (0.81–2.04) | 1.06 (0.88–1.29) |
| IS Model 2 | 1.00 (Reference) | 1.29 (0.79–2.10) | 1.11 (0.61–2.00) | 1.08 (0.84–1.32) |
| ICH Model 2 | 1.00 (Reference) | 1.35 (0.68–2.68) | 1.66 (0.76–3.63) | 1.03 (0.86–1.21) |
| SAH Model 2 | 1.00 (Reference) | 2.51 (0.33–12.03) | 1.11 (0.11–11.08) | 1.08 (0.76–1.40) |

| Hypertension | All/IS/ICH/SAH, n | 444/303/133/8 | 338/241/86/11 | 277/208/62/7 |
| All stroke Model 3 | 1.00 (Reference) | 1.19 (1.03–1.38)* | 1.29 (1.09–1.52)* | 1.11 (1.03–1.19)* |
| IS Model 3 | 1.00 (Reference) | 1.20 (1.01–1.43)* | 1.37 (1.13–1.66)* | 1.16 (1.06–1.26)** |
| ICH Model 3 | 1.00 (Reference) | 1.10 (0.84–1.46) | 1.06 (0.76–1.47) | 0.96 (0.85–1.09) |
| SAH Model 3 | 1.00 (Reference) | 2.23 (0.89–5.61) | 1.67 (0.53–5.26) | 1.62 (0.98–2.68) |

| Non-hypertension | All/IS/ICH/SAH, n | 208/139/59/10 | 102/74/25/3 | 103/84/18/1 |
| All stroke Model 3 | 1.00 (Reference) | 1.11 (0.87–1.42) | 1.49 (1.15–1.94)* | 1.20 (1.08–1.34)** |
| IS Model 3 | 1.00 (Reference) | 1.15 (0.86–1.53) | 1.69 (1.25–2.28)** | 1.34 (1.17–1.54)** |
| ICH Model 3 | 1.00 (Reference) | 1.11 (0.69–1.78) | 1.14 (0.65–1.98) | 0.96 (0.79–1.17) |
| SAH Model 3 | 1.00 (Reference) | 0.72 (0.19–2.65) | 0.41 (0.05–3.31) | 0.93 (0.54–1.59) |

*P<0.05, **P<0.001.
hs-CRP: high-sensitivity C-reactive protein; ICH: intracranial hemorrhage; IS: ischemic stroke; SAH: subarachnoid hemorrhage.
Model 1: adjusted for age and sex.
Model 2: adjusted for Model 1 and for hypertension, diabetes, dyslipidemia and for SBP, DBP, BMI, TC, TG, LDL, GLU, current smoking, alcohol intake, antihypertensive treatment, lipid-lowering treatment and hypoglycemic treatment.
Model 3: adjusted for Model 1 and for diabetes, dyslipidemia and for SBP, DBP, BMI, TC, TG, LDL, GLU, current smoking, alcohol intake, antihypertensive treatment, lipid-lowering treatment and hypoglycemic treatment.

doi:10.1371/journal.pone.0107017.t004
CRP concentrations and inflammation [36]. We were unable to adjust for these factors. However, at the baseline, only <1% participants took lipid-lowering medicine in this cohort, and even fewer participants changed medicine during the study. Thus the impact of the usage of lipid-lowering agents on the results can be neglected. Second, because of the industrial nature of Kailuan Community, there was an imbalance in gender distribution, more men than women. However, the incidence rates of stroke subtypes were similar in Chinese men and women [37], thus the influence of imbalance in gender distribution on the results would be minimal.

**Conclusion**

We observed that elevated hs-CRP concentrations were positively associated with the risk of ischemic stroke, particularly for non-fatal stroke, male and hypertensive subjects, but not of
intracranial hemorrhage and subarachnoid hemorrhage. Based on this large population study, CRP concentrations can be used as a clinical screen tool to identify individuals with higher risk of ischemic stroke in Chinese population.

Acknowledgments

The authors would like to thank the staff and participants of the APAC study for their important contributions.

References


Author Contributions

Conceived and designed the experiments: SW XZ XG. Performed the experiments: YL J Wang J Wu. Analyzed the data: YZ AW. Contributed reagents/materials/analysis tools: SW YL J Wang J Wu. Wrote the paper: YL J Wang LZ CW.